Redefining Korean Biopharma Partnerships with China: Addressing the Complex Regulatory & Geopolitical Friction

• Outlining the first example of a Korean CNS asset out-licensed at Phase III vs.typical earlier-stage licensing deals
• Demonstrating how Korean biopharma can retain and elevate their clinical assets to maximize financial returns
• Innovative collaboration models in the biopharma industry between Korea and China

Speakers:

Jae-Young Ha

Senior Vice President

AriBio